Evans, O;
Gaba, F;
Manchanda, R;
(2020)
Population-based genetic testing for Women's cancer prevention.
Best Practice & Research Clinical Obstetrics & Gynaecology
, 65
pp. 139-153.
10.1016/j.bpobgyn.2020.02.007.
Preview |
Text
Manchanda_PBGT Review_BPResCOG_v7.pdf - Accepted Version Download (809kB) | Preview |
Abstract
Germline mutations in cancer-susceptibility-genes (CSG) can dramatically increase womens' lifetime risk of ovarian, endometrial, breast and bowel cancers. Identification of unaffected carriers is important to enable proactive engagement with highly effective screening and preventive options to minimise cancer risk. Currently, a family-history model is used to identify individuals with CSGs. Complex regional referral guidelines specify the family-history criteria required before an individual is eligible for genetic-testing. This model is ineffective, resource intense, misses >50% CSG carriers, is associated with underutilisation of genetic-testing services and delays detection of mutation carriers. Although awareness and detection of CSG-carriers has improved, over 97% carriers remain unidentified. This reflects significant missed opportunities for precision-prevention. Population-based genetic-testing (PBGT) represents a novel healthcare strategy with the potential to dramatically improve detection of unaffected CSG-carriers along with enabling population risk-stratification for cancer precision-prevention. Several research studies have assessed the impact, feasibility, acceptability, long-term psychological outcomes and cost-effectiveness of population-based BRCA-testing in the Ashkenazi-Jewish population. Initial data on PBGT in the general-population is beginning to emerge and large implementation studies investigating PBGT in the general-population are needed. This review will summarise the current research into the clinical, psycho-social, health-economic, societal and ethical consequences of a PBGT model for women's cancer precision-prevention.
| Type: | Article |
|---|---|
| Title: | Population-based genetic testing for Women's cancer prevention |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.bpobgyn.2020.02.007 |
| Publisher version: | https://doi.org/10.1016/j.bpobgyn.2020.02.007 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | BRCA; Population-based genetic testing; Cancer; Ovarian; Breast; Lynch syndrome |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10100843 |
Archive Staff Only
 |
View Item |
